Psilocybin Moves the Social Brain in AUD, And Our Trial Endpoints Are Missing It

A pilot RCT links psilocybin's 25 mg dose to reduced egocentric bias in alcohol use disorder, exposing a blind spot in how psychedelic trials.

Share this story

Surfaced by 2 Google Alerts